VEGFD and lymphangioleiomyomatosis: Regarding tests involving Sirolimus, MILES trial included 89 patients with LAM and reported stabilized lung function, reduced serum VEGF-D levels that were associated with a reduction in symptoms and improvement in the quality of life for TSC patients with LAM (McCormack et al. 2011).